Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Hecht, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY.

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(10): 1108 Nº de citas: 74 [doi:10.1200/JCO.20.02232]

Sastre, J; Garcia-Alfonso, P; Vieitez, JM; Cano, MT; Rivera, F; Reina-Zoilo, JJ; Salud-Salvia, A; Quintero, G; Robles-Diaz, L; Safont, MJ; La Casta, A; Gil, S; Polo, E; Asensio-Martinez, E; Garcia-Paredes, B; Lopez, RL; Guillot, M; Valladares-Ayerbes, M; Aranda, E; Diaz-Rubio, E.

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and < 3 baseline circulating tumour cells: the randomised phase II VISNU-2 study

Esmo Open. 2021; 6(2): 100062-100062 Nº de citas: 7 [doi:10.1016/j.esmoop.2021.100062]

Morgan, G; Tagliamento, M; Lambertini, M; Devnani, B; Westphalen, B; Dienstmann, R; Bozovic-Spasojevic, I; Calles, A; Criscitiello, C; Curioni, A; Garcia, AM; Lamarca, A; Pilotto, S; Scheffler, M; Strijbos, M; Wong, R; de Azambuja, E; Peters, S.

Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network

Esmo Open. 2021; 6(2): 100104-100104 Nº de citas: 15 [doi:10.1016/j.esmoop.2021.100104]

Conde, E; Earl, J; Crespo-Toro, L; Blanco-Agudo, C; Ramos-Munoz, E; Rodriguez-Serrano, EM; Avila, JCM; Salinas-Munoz, L; Serrano-Huertas, S; Ferreiro, R; Rodriguez-Garrote, M; Sainz, B; Massuti, B; Alfonso, PG; Benavides, M; Aranda, E; Garcia-Bermejo, ML; Carrato, A.

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

Cancers. 2021; 13(7): Nº de citas: 8 [doi:10.3390/cancers13071710]

Trilla-Fuertes, L; Gamez-Pozo, A; Maurel, J; Garcia-Carbonero, R; Capdevila, J; G-Pastrian, L; Mendiola, M; Pena, C; Lopez-Vacas, R; Cuatrecasas, M; Garcia-Alfonso, P; Ramos-Ruiz, R; Llorens, C; Ghanem, I; Conill, C; Heredia-Soto, V; Campos-Barros, A; Vara, JAF; Feliu, J.

Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

Scientific Reports. 2021; 11(1): 7402-7402 Nº de citas: 3 [doi:10.1038/s41598-021-86966-w]

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Turner, N; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Anton, A; Kahan, Z; Csoszi, T; Casas, MI; Murillo, L; Morales, S; Alba, E; Gal-Yam, E; Guerrero-Zotano, A; Calvo, L; de la Haba-Rodriguez, J; Ramos, M; Alvarez, I; Garcia-Palomo, A; Bartlett, CH; Koehler, M; Caballero, R; Corsaro, M; Huang, X; Garcia-Saenz, JA; Chacon, JI; Swift, C; Thallinger, C; Gil-Gil, M.

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL

ANNALS OF ONCOLOGY. 2021; 32(4): 488-499 Nº de citas: 103 [doi:10.1016/j.annonc.2020.12.013]

Munoz-Langa, J; Jimenez-Fonseca, P; Carmona-Bayonas, A; de Castro, EM; Perez-Segura, P; Canovas, MS; Gomez, D; Moran, LO; de Tejada, MBG; Segui, E; Lopez, GB; Adrian, SG; Campos, MC; Olmos, VP; Portero, BO; Moyano, MS; Crespo, JAS; Sanchez, LT; Rebollo, MA; Rivas, PO; Altozano, JP; Lescure, AR; Munoz-Martin, A.

Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)

CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(4): 799-811 Nº de citas: 5 [doi:10.1007/s12094-020-02472-x]

Gonzalez-Barca, E; Capote, FJ; Gomez-Codina, J; Panizo, C; Salar, A; Sancho, JM; Lopez, A; Briones, J; Munoz, A; Encuentra, M; Mercadal, S; Domingo-Domenech, E; de Sevilla, AF.

Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients

ANNALS OF HEMATOLOGY. 2021; 100(4): 1023-1029 Nº de citas: 10 [doi:10.1007/s00277-020-04056-9]

Thavendiranathan, P; Zhang, LL; Zafar, A; Drobni, ZD; Mahmood, SS; Cabral, M; Awadalla, M; Nohria, A; Zlotoff, DA; Thuny, F; Heinzerling, LM; Barac, A; Sullivan, RJ; Chen, CL; Gupta, D; Kirchberger, MC; Hartmann, SE; Weinsaft, JW; Gilman, HK; Rizvi, MA; Kovacina, B; Michel, C; Sahni, G; Gonzalez-Mansilla, A; Calles, A; Fernandez-Aviles, F; Mahmoudi, M; Reynolds, KL; Ganatra, S; Gavira, JJ; Gonzalez, NS; Castro, MGD; Kwong, RY; Jerosch-Herold, M; Coelho, OR; Afilalo, J; Zatarain-Nicolas, E; Baksi, AJ; Wintersperger, BJ; Calvillo-Arguelles, O; Ederhy, S; Yang, EH; Lyon, AR; Fradley, MG; Neilan, TG.

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2021; 77(12): 1503-1516 Nº de citas: 148 [doi:10.1016/j.jacc.2021.01.050]

Martin, M; Ramos-Medina, R; Bernat, R; Garcia-Saenz, JA; del Monte-Millan, M; Alvarez, E; Cebollero, M; Moreno, F; Gonzalez-Haba, E; Bueno, O; Romero, P; Massarrah, T; Echavarria, I; Jerez, Y; Herrero, B; del Val, RG; Lobato, N; Rincon, P; Palomero, MI; Marquez-Rodas, I; Lizarraga, S; Asensio, F; Lopez-Tarruella, S.

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

Scientific Reports. 2021; 11(1): 7064-7064 Nº de citas: 14 [doi:10.1038/s41598-021-85962-4]

Mountzios, G; de Toma, A; Economopoulou, P; Friedlaender, A; Banini, M; Lo Russo, G; Baxevanos, P; Roila, F; Banna, GL; Christopoulou, A; Jimenez, B; Collazo-Lorduy, A; Linardou, H; Calles, A; Galetta, D; Addeo, A; Camerini, A; Pizzutilo, P; Kosmidis, P; Garassino, MC; Proto, C; Signorelli, D; Metro, G.

Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller

CLINICAL LUNG CANCER. 2021; 22(2): 180-192 Nº de citas: 14 [doi:10.1016/j.cllc.2020.09.017]

Rivera, F; Izquierdo-Manuel, M; Garcia-Alfonso, P; de Castro, EM; Gallego, J; Limon, ML; Alsina, M; Lopez, L; Galan, M; Falco, E; Manzano, JL; Gonzalez, E; Munoz-Unceta, N; Lopez, C; Aranda, E; Fernandez, E; Jorge, M; Jimenez-Fonseca, P.

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

EUROPEAN JOURNAL OF CANCER. 2021; 145: 158-167 Nº de citas: 54 [doi:10.1016/j.ejca.2020.12.005]

Garcia-Alfonso, P; Diaz-Rubio, E; Abad, A; Carrato, A; Massuti, B; Ortiz-Morales, MJ; Mozo, JLM; Munoz, A; Duran, G; Sastre, J; Safont, MJ; Ferreiro, R; Rivera, F; Gonzalez, E; Valladares-Ayerbes, M; Gravalos, C; Alonso-Orduna, V; Vieitez, JM; Yubero, A; Aranda, E.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

DRUGS & AGING. 2021; 38(3): 219-231 Nº de citas: 3 [doi:10.1007/s40266-021-00834-w]

Jimenez-Fonseca, P; Carmona-Bayonas, A; de Castro, EM; Custodio, A; Pijaume, CP; Hernandez, R; Aguado, G; Unanua, NC; Cano, JM; Lopez, F; Garrido, M; Montes, AF; Visa, L; Canovas, MS; Limon, ML; Lago, NM; Pimentel, P; Hurtado, A; Azkarate, A; Longo, F; Diez, M; Arias-Martinez, A; Sauri, T; Carnicero, AM; Mangas, M; Richard, MM; Granja, M; Ramchandani, A; Perez, CH; Cerda, P; Gil-Negrete, A; Calvo, M; Tocino, RV; Gallego, J.

External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?

Gastric Cancer. 2021; 24(2): 445-456 Nº de citas: 8 [doi:10.1007/s10120-020-01116-x]

Onesti, CE; Tagliamento, M; Curigliano, G; Harbeck, N; Bartsch, R; Wildiers, H; Tjan-Heijnen, V; Martin, M; Rottey, S; Generali, D; Campone, M; Cristofanilli, M; Pusztai, L; Peeters, M; Berchem, G; Cortes, J; Ruhstaller, T; Ciruelos, E; Rugo, HS; Jerusalem, G.

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

Jco Global Oncology. 2021; 7: 162-172 Nº de citas: 38 [doi:10.1200/GO.20.00589]

O'Shaughnessy, JA; Johnston, S; Harbeck, N; Toi, M; Im, YH; Reinisch, M; Shao, ZM; Lehtinen, PLK; Huang, CS; Tryakin, A; Goetz, M; Rugo, HS; Senkus, E; Testa, L; Andersson, M; Tamura, K; Steger, GG; Del Mastro, L; Cox, J; Forrester, T; Sherwood, S; Li, XL; Wei, R; Martin, M; Rastogi, P.

Primary Outcome Analysis of Invasive Disease-Free Survival for MonarchE: Abemaciclib Combined With Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 2021; 19(2): 15-16

Loibl, S; Marme, F; Martin, M; Untch, M; Bonnefoi, H; Kim, SB; Bear, H; Mc Carthy, N; Olive, MM; Gelmon, K; Saenz, JG; Kelly, CM; Reimer, T; Toi, M; Rugo, HS; Seiler, S; Nekljudova, V; Denkert, C; Gnant, M; Makris, A; Burchardi, N; von Minckwitz, G.

Phase III Study of Palbociclib Combined With Endocrine Therapy in Patients With Hormone Receptor-Positive, HER2-Negative Primary Breast Cancer and With High Relapse Risk After Neoadjuvant Chemotherapy: First Results From PENELOPE-B

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY. 2021; 19(2): 9-10

Tabernero, J; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Loupakis, F; Hong, YS; Steeghs, N; Guren, TK; Arkenau, HT; Garcia-Alfonso, P; Elez, E; Gollerkeri, A; Maharry, K; Christy-Bittel, J; Kopetz, S.

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

JOURNAL OF CLINICAL ONCOLOGY. 2021; 39(4): 273-284 Nº de citas: 362 [doi:10.1200/JCO.20.02088]